Replies to post #236532 on Biotech Values

[DewDiligence]

(MYOV)—…Perhaps…PFE wants more data first so the upfront can be viewed as a callable option if so.

The only meaningful Orgovyx data PFE has not yet seen are from the open-label extension study in endometriosis (https://www.clinicaltrials.gov/ct2/show/NCT03654274 ), which follows patients for 104 weeks (including the time on the original study). But even here, PFE has seen most of the data since the trial is open-label.